What is Novel Microdevices?
Novel Microdevices operates at the intersection of biotechnology and hardware engineering, focusing on the development of the Novel Dx device. This flagship technology is engineered to provide PCR-quality diagnostic results within minutes, effectively bridging the gap between slow, centralized laboratory testing and less accurate rapid antigen tests. By offering a multiplexed solution for infectious disease detection, the company addresses critical inefficiencies in current clinical workflows. Its market position is defined by a commitment to high-precision, portable diagnostics that maintain cost-competitiveness, thereby enabling broader access to molecular-level testing in decentralized healthcare settings.
How much funding has Novel Microdevices raised?
Novel Microdevices has raised a total of $3.6M across 2 funding rounds:
Other Financing Round
$2.6M
Debt
$1M
Other Financing Round (2024): $2.6M with participation from National Institutes of Health
Debt (2026): $1M, investors not publicly disclosed
Key Investors in Novel Microdevices
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical non-dilutive support for innovative medical technologies.
Undisclosed Investor
An undisclosed institutional partner participating in the latest debt financing round to support the company's operational scaling.
Undisclosed Investor
An undisclosed investor providing strategic backing to facilitate the commercial deployment of the Novel Dx diagnostic platform.
What's next for Novel Microdevices?
With the recent influx of capital, Novel Microdevices is poised to accelerate its commercialization strategy and scale manufacturing capabilities for the Novel Dx platform. The company is expected to prioritize regulatory milestones and clinical validation studies to expand its diagnostic menu. As the firm transitions from a development-focused entity to a commercial-stage enterprise, the focus will likely shift toward strategic partnerships with healthcare providers and global health organizations. This growth trajectory suggests a concerted effort to disrupt traditional diagnostic paradigms, aiming to establish the Novel Dx as a standard-of-care tool for rapid, actionable clinical decision-making in both domestic and international markets.
See full Novel Microdevices company page
